CNSP

CNS Pharmaceuticals, Inc.

3.67 USD
+0.54 (+17.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CNS Pharmaceuticals, Inc. stock is down -64.68% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 June’s closed higher than May.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials.